Reuters (8/29, Sunny) reported the FDA on Friday approved an injectable version of Eisai and Biogen’s Alzheimer’s disease drug Leqembi (lecanemab), “allowing for an easier treatment option following an initial intravenous infusion. The approval makes Leqembi the first Alzheimer’s treatment that can be administered at home as a weekly under-the-skin injection, reducing the hassle for patients who now need to travel to an infusion center twice a month for the process that takes about an hour.” The injectable version, branded as Leqembi IQLIK, “was approved as a maintenance dose for patients who have completed 18 months of bi-weekly intravenous (IV) infusions, the companies said. Patients would also have the option to continue IV infusions once every month as maintenance instead of the weekly subcutaneous injection.” (SOURCE: APA Headlines)